Latest Cash Runway News

Gold Mountain Limited has delivered a transformational quarter, confirming significant rare earth and lithium mineralisation in Brazil and securing $3.57 million in fresh capital to advance exploration.

Jindalee Lithium Limited reported a cash outflow for the December 2025 quarter but maintains a solid cash position of A$6.5 million, with an estimated funding runway of 1.67 quarters. The company remains confident in securing additional financing to support its pre-development activities.

Codrus Minerals reports encouraging initial diamond drilling results at its Bull Run Gold Project in Oregon, while progressing uranium exploration in Canada and executing a significant asset sale in Western Australia.

Auravelle Metals has reported significant high-grade gold intersections at its Sheoak Prospect in South Australia, extending the gold trend beyond 600 metres and identifying new targets at Sheoak East. Meanwhile, early drilling at its Crown Gold Project in Western Australia confirms extensive gold anomalism, supported by a successful $2.5 million capital raise to fund ongoing exploration.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting rare genetic diseases, supported by a strong cash position of $121 million at the end of 2025. Key clinical milestones and regulatory plans set the stage for upcoming trial readouts and potential market entry.

Buxton Resources reported robust exploration progress in the December 2025 quarter, highlighted by significant silver and copper-gold assay results and strategic tenement expansions. Leadership changes and cost management measures position the company for focused discovery efforts ahead.

Kali Metals has completed its inaugural drilling campaign at the Marble Bar Gold Project and a comprehensive soil sampling program at Higginsville Lithium, with assay results anticipated in the first quarter of 2026.

Invex Therapeutics reports promising new data from its collaboration with Tessara Therapeutics on Exenatide’s potential in Alzheimer’s disease, alongside significant board changes and a solid cash position at quarter’s end.

OZZ Resources has entered a binding option agreement with Scorpion Minerals to sell its Maguires Reward project, securing an initial $100,000 fee and potential $2.5 million consideration pending shareholder approval. Exploration activity remained subdued across its portfolio during the December quarter.

Memphasys Limited has achieved its first material revenues following CE Mark approval for its Felix™ System, activating multi-year contracts across Europe, the Middle East, and Asia. The company is now transitioning from regulatory preparation to global commercial rollout with a focus on recurring revenues.

Ion Video Limited has completed significant restructuring, strengthened its Melbourne-based tech team, and raised $2.95 million, positioning itself for a technology relaunch in February 2026 with a cash runway extending to mid-2027.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.